A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Conditions: Triple Negative Breast Cancer; Residual Disease Interventions: Drug: Tetrathiomolybdate; Drug: Capecitabine; Drug: Pembrolizumab Sponsors: Dartmouth-Hitchcock Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
Conditions: Colonic Neoplasms; Neoadjuvant Therapy; Immune Checkpoint Inhibitors Interventions: Drug: Anti-PD-1 monoclonal antibody; Drug: Oxaliplatin; Drug: Capecitabine 500 MG; Procedure: Colectomy Sponsors: First Affiliated Hospital of Guangxi Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: BL-B01D1; Drug: capecitabine; Drug: gemcitabine; Drug: docetaxel Sponsors: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer
Conditions: Colorectal Carcinoma Interventions: Drug: Fruquintinib 、Capecitabine Tablets Sponsors: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Dato-DXd; Drug: Durvalumab; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Carboplatin; Drug: Capecitabine; Drug: Olaparib Sponsors: AstraZeneca; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study of Rilvegostomig Plus Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection
Conditions: Biliary Tract Cancer Interventions: Drug: Rilvegostomig; Drug: Placebo; Drug: Capecitabine; Drug: Gemcitabine/Cisplatin; Drug: S-1 [Tegafur/Oteracil/gimeracil] Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Conditions: Pancreas Cancer; Pancreas Adenocarcinoma Interventions: Drug: Capecitabine Sponsors: Lee Ocuin, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
Conditions: Metastatic Breast Cancer Interventions: Drug: Capecitabine Pill Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Conditions: HER2-negative Breast Cancer; Advanced Breast Cancer Interventions: Drug: Organoid-guided treatment; Drug: Taxane; Drug: Capecitabine; Drug: Gemcitabine; Drug: Vinorelbine; Drug: Eribulin Sponsors: Guangdong Provincial People ' s Hospital; First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Shantou Central Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Combination Product: CCRT with Maintenance Tislelizumab and Metronomic Capecitabine Sponsors: National Cancer Centre, Singapore; BeiGene; Tan Tock Seng Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Conditions: Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer Interventions: Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU); Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU) Sponsors: Suzhou Transcenta Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
BRE-08: A Phase II Study of an All-Oral Adjuvant Chemotherapy Regimen of Cyclophosphamide, Methotrexate, and Capecitabine (CMC) for Early-Stage Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Capecitabine Sponsors: University of Illinois at Chicago Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Capecitabine Sponsors: University of Illinois at Chicago Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Conditions: Metastatic Breast Cancer Interventions: Drug: SKB264; Drug: Eribulin; Drug: Capecitabine; Drug: Gemcitabine; Drug: Vinorelbine Sponsors: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Conditions: Breast Cancer Interventions: Drug: JSKN003; Drug: Capecitabine tablets; Drug: Gemcitabine hydrochloride for injection; Drug: Vinorelbine tartrate injection; Drug: Paclitaxel for injection (albumin-bound type); Drug: Docetaxel injection; Drug: Eribulin mesylate injection Sponsors: Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
